Daniel Ripley
Plus aucun poste en cours
Profil
Daniel L.
Ripley worked as a Director or Senior Director of Business Development in various pharmaceutical companies such as Ionis Pharmaceuticals, Kalypsys, The Immune Response Corporation, Apricus Biosciences, BioBlocks, and Conatus Pharmaceuticals.
He also worked as an Associate Director of Business Development in Orchestra Therapeutics, and as a Senior Vice President of Business Development in Hightide Therapeutics.
Ripley holds an undergraduate degree and an MBA from San Diego State University.
Anciens postes connus de Daniel Ripley
| Sociétés | Poste | Fin |
|---|---|---|
| HISTOGEN INC. | Directeur/Membre du Conseil | 02/10/2012 |
Apricus Biosciences, Inc.
 Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/01/2012 |
BioBlocks, Inc.
 BioBlocks, Inc. BiotechnologyHealth Technology Part of Genesis Biotechnology Group LLC, BioBlocks, Inc. is a collaborative medicinal chemistry research organization based in San Diego, CA. The company focuses on drug discovery from initial hit through identification of development candidates. BioBlocks provides expertise and joins forces with its clients to discover compounds qualified for advancement to phase two clinical trials. Aided by a results-based lead optimization model, BioBlocks scientists have developed multiple preclinical candidates for its partners. The company's leap-to-lead platform provides an alternative source for high-quality tractable leads with multiple possible optimization pathways. The company was founded in 2002 by Peter Pallai, who has been the CEO since 2002. BioBlocks was acquired by Genesis Drug Discovery & Development LLC on October 07, 2021. | Corporate Officer/Principal | 01/01/2010 |
Kalypsys, Inc.
 Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Corporate Officer/Principal | 01/01/2008 |
| IONIS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/01/2006 |
Formation de Daniel Ripley
| San Diego State University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IONIS PHARMACEUTICALS, INC. | Health Technology |
| HIGHTIDE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Orchestra Therapeutics, Inc.
 Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | Finance |
Apricus Biosciences, Inc.
Apricus Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Apricus Biosciences, Inc. is a biopharmaceutical company, which engages in the development and commercialization of product candidates in the areas of specialty urology and rheumatology. Its products include Vitaros and Femprox. The company was founded in 1987 and is headquartered in San Diego, CA. | Health Technology |
Kalypsys, Inc.
Kalypsys, Inc. Pharmaceuticals: MajorHealth Technology Kalypsys, Inc. discovered and developed novel, first-in-class therapeutic agents to address unmet medical needs in respiratory and inflammatory diseases. The firm advanced its proprietary lead program, a novel, non-corticosteroid small molecule formulated for intranasal delivery, into clinical proof of concept studies. The company was founded by Pratik Shah, Jeremy S. Caldwell, Randall W. King, Kevin D. Lustig, Peter G. Schultz and Robert Downs in 2001 and was headquartered in Solana Beach, CA. | Health Technology |
Conatus Pharmaceuticals, Inc.
 Conatus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA. | Health Technology |
BioBlocks, Inc.
BioBlocks, Inc. BiotechnologyHealth Technology Part of Genesis Biotechnology Group LLC, BioBlocks, Inc. is a collaborative medicinal chemistry research organization based in San Diego, CA. The company focuses on drug discovery from initial hit through identification of development candidates. BioBlocks provides expertise and joins forces with its clients to discover compounds qualified for advancement to phase two clinical trials. Aided by a results-based lead optimization model, BioBlocks scientists have developed multiple preclinical candidates for its partners. The company's leap-to-lead platform provides an alternative source for high-quality tractable leads with multiple possible optimization pathways. The company was founded in 2002 by Peter Pallai, who has been the CEO since 2002. BioBlocks was acquired by Genesis Drug Discovery & Development LLC on October 07, 2021. | Health Technology |
| The Immune Response Corporation, Inc. |
